Matches in SemOpenAlex for { <https://semopenalex.org/work/W3121324497> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W3121324497 abstract "Objective: Evaluate the efficacy and side-effect profile of Perampanel as adjunctive therapy for refractory epilepsy. Background: Epilepsy affects approximately 1.2 million Americans and 30% of them remain medically intractable. Newly FDA-approved medications are of interest for patients who have failed multiple classes of antiepileptic drugs (AEDs) and/or surgical procedures. Perampanel is an orally active, non-competitive AMPA-type glutamate receptor antagonist approved for adjunctive treatment of refractory epilepsy based on the efficacy and safety results of Phase III double-blind studies. Perampanel was shown to reduce seizure frequency in patients receiving 1–3 concomitant AEDs. Design/Methods: Retrospective review conducted on patients who were 12 years of age or older treated with perampanel at Baylor Scott & White Hospital/Texas A&M College of Medicine in Temple, TX. Subject data were acquired from electronic medical records. Approval was given by our hospital’s Institutional Review Board. Patient demographics included age, gender, epilepsy type, concomitant/failed anticonvulsants, and seizure frequency. Outcome measures were efficacy and tolerability of perampanel. Results: A total 18 patients met our inclusion criteria. Demographics included 12 males (66%), 6 females (33%), ages ranging 14–75 years. Partial epilepsy was diagnosed in 12 patients (66%) and generalized epilepsy in 6 (33%). The majority of patients, 13 (72.2%), were on 1–3 AEDs, 3 (17%) were on 0–1 AED, and 2 (11.1%) were on 4+ AEDs prior to receiving perampanel. Starting doses were 2–4mg daily, maintenance 4–8mg daily. Primary objective was response to perampanel: seizure frequency reduction in 12 (66.6%), no change in 3 (16.6%), and increased frequency in 3 (16.6%). A total of 8 (44.4%) patients came off perampanel; 5 (27.7%) due to aggressiveness/behavioral changes, 3 (16.6%) had sedation, dizziness, or ineffectiveness. Follow-up was 3 months - 1 year in clinic. Conclusions: Study limited by small sample size. Perampanel was beneficial in patients with refractory partial or generalized epilepsy as adjunctive therapy. Mostly behavioral side-effects were observed. Disclosure: Dr. Barr has nothing to disclose. Dr. Gomez has nothing to disclose. Dr. Castillo has nothing to disclose. Dr. Kirmani has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sunovion Pharmaceuticals and Lundbeck." @default.
- W3121324497 created "2021-02-01" @default.
- W3121324497 creator A5042944644 @default.
- W3121324497 creator A5047496478 @default.
- W3121324497 creator A5075149548 @default.
- W3121324497 creator A5079810132 @default.
- W3121324497 date "2019-04-09" @default.
- W3121324497 modified "2023-09-23" @default.
- W3121324497 title "Efficacy and Tolerability of Perampanel as Adjunctive Therapy in Refractory Epilepsy (P3.5-020)" @default.
- W3121324497 hasPublicationYear "2019" @default.
- W3121324497 type Work @default.
- W3121324497 sameAs 3121324497 @default.
- W3121324497 citedByCount "0" @default.
- W3121324497 crossrefType "journal-article" @default.
- W3121324497 hasAuthorship W3121324497A5042944644 @default.
- W3121324497 hasAuthorship W3121324497A5047496478 @default.
- W3121324497 hasAuthorship W3121324497A5075149548 @default.
- W3121324497 hasAuthorship W3121324497A5079810132 @default.
- W3121324497 hasConcept C118552586 @default.
- W3121324497 hasConcept C121332964 @default.
- W3121324497 hasConcept C126322002 @default.
- W3121324497 hasConcept C142424586 @default.
- W3121324497 hasConcept C187212893 @default.
- W3121324497 hasConcept C197934379 @default.
- W3121324497 hasConcept C2778186239 @default.
- W3121324497 hasConcept C2778375690 @default.
- W3121324497 hasConcept C2778715236 @default.
- W3121324497 hasConcept C2779384505 @default.
- W3121324497 hasConcept C2780836401 @default.
- W3121324497 hasConcept C3018162438 @default.
- W3121324497 hasConcept C71924100 @default.
- W3121324497 hasConcept C87355193 @default.
- W3121324497 hasConceptScore W3121324497C118552586 @default.
- W3121324497 hasConceptScore W3121324497C121332964 @default.
- W3121324497 hasConceptScore W3121324497C126322002 @default.
- W3121324497 hasConceptScore W3121324497C142424586 @default.
- W3121324497 hasConceptScore W3121324497C187212893 @default.
- W3121324497 hasConceptScore W3121324497C197934379 @default.
- W3121324497 hasConceptScore W3121324497C2778186239 @default.
- W3121324497 hasConceptScore W3121324497C2778375690 @default.
- W3121324497 hasConceptScore W3121324497C2778715236 @default.
- W3121324497 hasConceptScore W3121324497C2779384505 @default.
- W3121324497 hasConceptScore W3121324497C2780836401 @default.
- W3121324497 hasConceptScore W3121324497C3018162438 @default.
- W3121324497 hasConceptScore W3121324497C71924100 @default.
- W3121324497 hasConceptScore W3121324497C87355193 @default.
- W3121324497 hasLocation W31213244971 @default.
- W3121324497 hasOpenAccess W3121324497 @default.
- W3121324497 hasPrimaryLocation W31213244971 @default.
- W3121324497 hasRelatedWork W1953623782 @default.
- W3121324497 hasRelatedWork W2060121528 @default.
- W3121324497 hasRelatedWork W2128527749 @default.
- W3121324497 hasRelatedWork W2341866581 @default.
- W3121324497 hasRelatedWork W2414249837 @default.
- W3121324497 hasRelatedWork W2470130418 @default.
- W3121324497 hasRelatedWork W2500514079 @default.
- W3121324497 hasRelatedWork W2560633658 @default.
- W3121324497 hasRelatedWork W2564950111 @default.
- W3121324497 hasRelatedWork W2790471096 @default.
- W3121324497 hasRelatedWork W2807709077 @default.
- W3121324497 hasRelatedWork W2810385853 @default.
- W3121324497 hasRelatedWork W2897207431 @default.
- W3121324497 hasRelatedWork W2912177640 @default.
- W3121324497 hasRelatedWork W3000507271 @default.
- W3121324497 hasRelatedWork W3007846448 @default.
- W3121324497 hasRelatedWork W3011775057 @default.
- W3121324497 hasRelatedWork W3036431220 @default.
- W3121324497 hasRelatedWork W3089252390 @default.
- W3121324497 hasRelatedWork W3205689668 @default.
- W3121324497 hasVolume "92" @default.
- W3121324497 isParatext "false" @default.
- W3121324497 isRetracted "false" @default.
- W3121324497 magId "3121324497" @default.
- W3121324497 workType "article" @default.